Biology Reference
In-Depth Information
14. Drexler I, Staib C, Sutter G (2004) Modified vaccinia virus Ankara as antigen
delivery system: how can we best use its potential? Curr Opin Biotechnol 15:
506-512.
15. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, et al. (2004) Immuno-
genicity of a highly attenuated MVA smallpox vaccine and protection against
monkeypox. Nature 428: 182-185.
16. Mayr A (2003) Smallpox vaccination and bioterrorism with pox viruses. Comp
Immunol Microbiol Infect Dis 26: 423-430.
17. Cosma A, Nagaraj R, Staib C, Diemer C, Wopfner F, et al. (2007) Evaluation
of modified vaccinia virus Ankara as an alternative vaccine against smallpox in
chronically HIV type 1-infected individuals undergoing HAART. AIDS Res
Hum Retroviruses 23: 782-793.
18. Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, et al. (2006)
Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuber-
culosis. Vaccine 24: 4554-4561.
19. Hanke T, McMichael AJ, Dorrell L (2007) Clinical experience with plasmid
DNA- and modified vaccinia virus Ankara-vectored human immunodeficien-
cy virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol 88:
1-12.
20. Kent S, De Rose R, Rollman E (2007) Drug evaluation: DNA/MVA prime-
boost HIV vaccine. Curr Opin Investig Drugs 8: 159-167.
21. McShane H, Hill A (2005) Prime-boost immunisation strategies for tuberculo-
sis. Microbes Infect 7: 962-967.
22. Skeiky YA, Sadoff JC (2006) Advances in tuberculosis vaccine strategies. Nat
Rev Microbiol 4: 469-476.
23. Hill AV (2006) Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat
Rev Immunol 6: 21-32.
24. Reyes-Sandoval A, Harty JT, Todryk SM (2007) Viral vector vaccines make
memory T cells against malaria. Immunology 121: 158-165.
25. Keating SM, Bejon P, Berthoud T, Vuola JM, Todryk S, et al. (2005) Durable
human memory T cells quantifiable by cultured enzyme-linked immunospot
assays are induced by heterologous prime boost immunization and correlate
with protection against malaria. J Immunol 175: 5675-5680.
26. Bejon P, Mwacharo J, Kai O, Mwangi T, Milligan P, et al. (2006) A phase 2b
randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA
ME-TRAP among children in Kenya. PLoS Clin Trials 1: e29.
Search WWH ::




Custom Search